[1] Bajaj J S, Khoruts A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis[J]. J Hepatol, 2020,72(5): 1003-1027.
[2] Piano S, Singh V, Caraceni P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide[J]. Gastroenterology, 2019,156(5): 1368-1380 e10.
[3] Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis[J]. Semin Liver Dis, 2008, 28(1): 26-42.
[4] Bernsmeier C, van der Merwe S, Périanin A. Innate immune cells in cirrhosis[J]. J Hepatol, 2020, 73(1):186-201.
[5] Artru F, Bou Saleh M, Maggiotto F, et al. IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis[J]. J Hepatol, 2020,72(6):1052-1061.
[6] Stadlbauer V, Mookerjee R P, Wright G A, et al. Role of toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis[J]. Am J Physiol Gastrointest Liver Physiol, 2009,296(1):G15-G22.
[7] Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease[J]. Nat Rev Immunol, 2017,17(5):306-321.
[8] Wang R, Tang R, Li B, et al. Gut microbiome, liver immunology, and liver diseases[J]. Cell Mol Immunol, 2021,18(1): 4-17.
[9] McGettigan B, McMahan R, Orlicky D, et al.Dietary lipids differentially shape nonalcoholic steatohepatitis progression and the transcriptome of Kupffer cells and infiltrating macrophages[J]. Hepatology, 2019,70(1):67-83.
[10] Bernsmeier C, Pop O T, Singanayagam A, et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK[J]. Gastroenterology, 2015,148(3): 603-615 e14.
[11] Noor M T, Manoria P. Immune dysfunction in cirrhosis[J]. J Clin Transl Hepatol, 2017,5(1):50-58.
[12] Lario M, Mu?oz L, Ubeda M, et al. Defective thymopoiesis and poor peripheral homeostatic replenishment of T-helper cells cause T-cell lymphopenia in cirrhosis[J]. J Hepatol, 2013,59(4):723-730.
[13] Albillos A, Lario M, ?lvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance[J]. J Hepatol, 2014,61(6):1385-1396.
[14] Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: a critical review and practical guidance[J]. World J Hepatol, 2016,8(6):307-321.
[15] Fernández J, Navasa M, Gómez J, et al.Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis[J]. Hepatology, 2002, 35(1):140-148.
[16] Bernard B, Grangé J D, Khac E N, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis[J]. Hepatology, 1999,29(6):1655-1661.
[17] Bunchorntavakul C, Chavalitdhamrong D. Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis[J]. World J Hepatol, 2012, 4(5):158-168.
[18] Kim A, Song B G, Kang W, et al. Prevalence and predictors of multidrug-resistant bacteremia in liver cirrhosis[J]. Korean J Intern Med, 2024, 39(3):448-457.
[19] Li B, Yang C, Qian Z, et al. Spontaneous fungal ascites infection in patients with cirrhosis: an analysis of 10 cases[J]. Infect Dis Ther, 2021,10(2): 1033-1043.
[20] Chen J, Yang Q, Huang J, et al. Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study[J]. Int J Med Sci, 2013,10(12): 1625-1631.
[21] Lucifora J, Michelet M, Rivoire M, et al. Two-dimensional-cultures of primary human hepatocytes allow efficient HBV infection: old tricks still work![J]. J Hepatol, 2020,73(2):449-451.
[22] Marjot T, Moon A M, Cook J A, et al.Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study[J]. J Hepatol, 2021,74(3):567-577. |
